These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 37591705)
41. Quantification of pertussis toxin, filamentous haemagglutinin, 69 kDa outer membrane protein, agglutinogens 2 and 3 and lipopolysaccharide in the Danish whole-cell pertussis vaccine. Ibsen PH; Petersen JW; Heron I Vaccine; 1993; 11(3):318-22. PubMed ID: 8447160 [TBL] [Abstract][Full Text] [Related]
42. Responses to primary and a booster dose of acellular, component, and whole-cell pertussis vaccines initiated at 2 months of age. Huang LM; Lee CY; Lin TY; Chen JM; Lee PI; Hsu CY Vaccine; 1996 Jun; 14(9):916-22. PubMed ID: 8843635 [TBL] [Abstract][Full Text] [Related]
43. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Cherry JD; Gornbein J; Heininger U; Stehr K Vaccine; 1998 Dec; 16(20):1901-6. PubMed ID: 9796041 [TBL] [Abstract][Full Text] [Related]
44. Characteristics and potency of an acellular pertussis vaccine composed of pertussis toxin, filamentous hemagglutinin, and pertactin. Sheu GC; Wo YY; Yao SM; Chou FY; Hsu TC; Ju CL; Cheng Y; Chang SN; Lu CH J Microbiol Immunol Infect; 2001 Dec; 34(4):243-51. PubMed ID: 11825003 [TBL] [Abstract][Full Text] [Related]
45. Approaches to the control of acellular pertussis vaccines. Corbel MJ; Xing DK; Bolgiano B; Hockley DJ Biologicals; 1999 Jun; 27(2):133-41. PubMed ID: 10600202 [TBL] [Abstract][Full Text] [Related]
46. A randomised controlled trial with a diphtheria-tetanus-acellular pertussis (dTpa) vaccine in adults. Van der Wielen M; Van Damme P; Joossens E; François G; Meurice F; Ramalho A Vaccine; 2000 Apr; 18(20):2075-82. PubMed ID: 10715521 [TBL] [Abstract][Full Text] [Related]
47. Effect of FHA and Prn on Bordetella pertussis colonization of mice is dependent on vaccine type and anatomical site. Zeddeman A; van Schuppen E; Kok KE; van Gent M; Heuvelman KJ; Bart MJ; van der Heide HGJ; Gillard J; Simonetti E; Eleveld MJ; van Opzeeland FJH; van Selm S; de Groot R; de Jonge MI; Mooi FR; Diavatopoulos DA PLoS One; 2020; 15(8):e0237394. PubMed ID: 32822419 [TBL] [Abstract][Full Text] [Related]
48. Simple, efficient purification of filamentous hemagglutinin and pertussis toxin from Bordetella pertussis by hydrophobic and affinity interaction. Skelton SK; Wong KH J Clin Microbiol; 1990 May; 28(5):1062-5. PubMed ID: 2351723 [TBL] [Abstract][Full Text] [Related]
49. Cell-mediated immunity after pertussis vaccination and after natural infection. Zepp F; Knuf M; Habermehl P; Schmitt HJ; Meyer C; Clemens R; Slaoui M Dev Biol Stand; 1997; 89():307-14. PubMed ID: 9272364 [TBL] [Abstract][Full Text] [Related]
50. Comparison of a three-component acellular pertussis vaccine with a whole-cell pertussis vaccine in 4- through 6-year-old children. Elmwood Pediatric Associates, Pennridge Pediatric Associates. Annunziato PW; Rothstein EP; Bernstein HH; Blatter MM; Reisinger KS; Pichichero ME Arch Pediatr Adolesc Med; 1994 May; 148(5):503-7. PubMed ID: 8180641 [TBL] [Abstract][Full Text] [Related]
51. Development and validation of enzyme-linked immunosorbent assay for anti-mouse pertussis immunoglobulin G using international reference anti- Kang KR; Kwon YH; Cho GW; Choi GS; Ji JH; Kang HM; Lee SY; Kang JH Clin Exp Vaccine Res; 2024 Jul; 13(3):242-252. PubMed ID: 39144122 [TBL] [Abstract][Full Text] [Related]
52. Expression, Purification and Characterization of Three Overlapping Immunodominant Recombinant Fragments from Bordetella pertussis Filamentous Hemagglutinin. Asgarian-Omran H; Amirzargar AA; Arjmand M; Eshraghian M; Nikbin B; Eshraghi S; Mahdavi M; Khoshnoodi J; Jeddi-Tehrani M; Rabbani H; Shokri F Avicenna J Med Biotechnol; 2013 Jan; 5(1):20-8. PubMed ID: 23626873 [TBL] [Abstract][Full Text] [Related]
53. Capillary electrophoresis for purity estimation and in-process testing of recombinant GB virus-C proteins. Kundu S; Fenters C; Lopez M; Varma A; Brackett J; Kuemmerle S; Hunt JC J Capillary Electrophor; 1997; 4(1):7-13. PubMed ID: 9384714 [TBL] [Abstract][Full Text] [Related]
54. A novel bivalent acellular pertussis vaccine based on the 69 kDa protein and FHA. Novotny P; Chubb AP; Cownley K; Charles IG Dev Biol Stand; 1991; 73():243-9. PubMed ID: 1778316 [TBL] [Abstract][Full Text] [Related]
55. Further characterization of Japanese acellular pertussis vaccine prepared in 1988 by 6 Japanese manufacturers. Sato Y; Sato H Tokai J Exp Clin Med; 1988; 13 Suppl():79-88. PubMed ID: 2908530 [TBL] [Abstract][Full Text] [Related]
56. Online top-down mass spectrometric identification of CE(SDS)-separated antibody fragments by two-dimensional capillary electrophoresis. Römer J; Stolz A; Kiessig S; Moritz B; Neusüß C J Pharm Biomed Anal; 2021 Jul; 201():114089. PubMed ID: 33940498 [TBL] [Abstract][Full Text] [Related]
57. Characterization of the filamentous hemagglutinin from Bordetella pertussis by gel electrophoresis. An der Lan B; Cowell JL; Burstyn DG; Manclark CR; Chrambach A Mol Cell Biochem; 1986 Apr; 70(1):31-55. PubMed ID: 2872590 [TBL] [Abstract][Full Text] [Related]
58. A novel method for evaluating natural and vaccine induced serological responses to Bordetella pertussis antigens. Berbers GA; van de Wetering MS; van Gageldonk PG; Schellekens JF; Versteegh FG; Teunis PF Vaccine; 2013 Aug; 31(36):3732-8. PubMed ID: 23742995 [TBL] [Abstract][Full Text] [Related]
59. Rapid purification of pertussis toxin (PT) and filamentous hemagglutinin (FHA) by cation-exchange chromatography. Ozcengiz E; Kilinç K; Büyüktanir O; Günalp A Vaccine; 2004 Mar; 22(11-12):1570-5. PubMed ID: 15063583 [TBL] [Abstract][Full Text] [Related]
60. Evaluation of Outer Membrane Vesicles Obtained from Predominant Local Isolate of Boredetella pertussis as a Vaccine Candidate. Soltani MS; Noofeli M; Banihashemi SR; Shahcheraghi F; Eftekhar F Iran Biomed J; 2021 Nov; 25(6):399-407. PubMed ID: 34719226 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]